Drugs / OPC-131461
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06795399 | Apr → May 2025 | heart failure | Otsuka Pharmaceutical Development & Commercialization, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05615363 | Jan 2023 → Oct 2024 | congestive heart failure | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPC-131461 | “OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days” NCT05615363 ↗ |
| Route | Oral | “once-daily oral administration” NCT05615363 ↗ |